Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TSR-022 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1a: TSR-022 monotherapy | EXPERIMENTAL | - |
| Part 1b: TSR-022 in combination with nivolumab | EXPERIMENTAL | - |
| Part 1c: TSR-022 in combination with TSR-042 | EXPERIMENTAL | - |
| Part 1d: TSR-022 in combination with TSR-042 and TSR-033 | EXPERIMENTAL | - |
| Part 1e: TSR-022 with TSR-042 (not previously treated with anti-programmed death ligand [PD-{L}]1) | EXPERIMENTAL | - |
| Part 1f: TSR-022 in combination with TSR-042 and Docetaxel | EXPERIMENTAL | - |
| Part 1g: TSR-022 in combination with TSR-042, pemetrexed, and cisplatin | EXPERIMENTAL | - |
| Part 1h: TSR-022 in combination with TSR-042, pemetrexed, and carboplatin | EXPERIMENTAL | - |
| Part 2: Cohort A Melanoma-TSR-022 as monotherapy | EXPERIMENTAL | - |
| Part 2: Cohort A Melanoma-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2:Cohort B Non-small cell lung cancer-TSR-022-monotherapy | EXPERIMENTAL | - |
| Part 2:Cohort B Non-small cell lung cancer-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2:Cohort C Colorectal cancer-TSR-022 as monotherapy | EXPERIMENTAL | - |
| Part 2:Cohort C Colorectal cancer-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2: Cohort D-TIM-3 selected non-small cell lung cancer (NSCLC)-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Part 2: Cohort E-Non-small cell lung cancer-TSR-022 with docetaxel | EXPERIMENTAL | - |
| Part 2: Cohort F- Hepatocellular carcinoma (HCC)-TSR-022 with TSR-042 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| TSR-022 | DRUG | TSR-022 will be administered. |
| Nivolumab | DRUG | Nivolumab will be administered. |
| TSR-042 | DRUG | TSR-042 will be administered. |
| TSR-033 | DRUG | TSR-033 will be administered. |
| Docetaxel | DRUG | Docetaxel will be administered. |
| Pemetrexed | DRUG | Pemetrexed will be administered. |
| Cisplatin | DRUG | Cisplatin will be administered. |
| Carboplatin | DRUG | Carboplatin will be administered. |
Inclusion Criteria * Participant is at least 18 years of age. * Female participants of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the date of the first dose of study medication or be of non-childbearing potential. * Participant has an ECOG per...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | ACE-536 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, Ruxolitinib |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor, Ruxolitinib |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Incyte Corporation | INCY | 10 | PHASE2 | Ruxolitinib |
| GSK plc Sponsored ADR | GSK | 2 | PHASE2 | MMB |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Elritercept, Ruxolitinib |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY3410738, Venetoclax, Azacitidine |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Galecto, Inc. | GLTO | 1 | PHASE2 | GB2064 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | bomedemstat |
TSR-022 is an investigational small molecule being studied for the treatment of neoplasms, which are abnormal growths of tissue that can be benign or malignant. It is currently in Phase 1 clinical development for this oncology indication.
TSR-022 is a small molecule, but its specific molecular target has not been disclosed. It is being investigated for its potential role in treating neoplasms, though the exact mechanism of action is not publicly available.
TSR-022 is being developed by GSK plc, a global biopharmaceutical company. GSK is listed on the stock exchange under the ticker symbol GSK.
TSR-022 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The drug is being studied in an active clinical trial for advanced solid tumors.
TSR-022 is being studied in a Phase 1 clinical trial with the identifier NCT02817633, known as the AMBER study. This trial is investigating TSR-022 in participants with advanced solid tumors and is active but not recruiting. The trial has enrolled 463 participants across the United States, South Korea, and Spain.
TSR-022 is a unique investigational drug candidate. No alternative names for TSR-022 have been disclosed, and it is not known to be the same as any other approved or investigational medication.